[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Contact ::
Main Menu
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Contact us::
Site Facilities::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Last site contents
:: Editorial Board
:: About Iranian Journal of Endocrinology and Metabolism
:: Volume 11, Issue 2 (3-2010) ::
2010, 11(2): 151-157 Back to browse issues page
Serum Visfatin Concentration in Patients with Metabolic Syndrome
M Foroughi , MJ Hosseinzadeh , S Zahediasl , F. Hoseinpanah , AA Momenan , MR Eshraghiyan , AA Saboor Yaraghi
, mjha3@yahoo.com
Abstract:   (27002 Views)


Introduction: Recent studies indicate that Visfatin, a newly identified adipocytokine, may have potential proinflammatory effects. Since, the relationship between serum visfatin levels and metabolic syndrome (MetS) has not been established, the aim of this study was to explore the association between serum visfatin levels and anthropometric variables and the metabolic syndrome. Materials and Methods: Thirty-seven patients with MetS and 37 age matched controls (mean age 46.35±1.6 years) were included. Metabolic syndrome in patients was defined based on the 2005 criteria of the International Diabetes Federation, and anthropometric and biochemical profiles were documented. Serum Visfatin was measured using an enzyme immunoassay (EIA) kit. Using the t-test, data were compared between groups and Pearson's correlation coefficient was used to evaluate the relationship between continuous variables. P values <0.05 were considered as statistically significant. Results: Serum Visfatin level was significantly lower in metabolic syndrome patients (P<0. 05) compared controls, log visfatin: 1.74 ± 0.27ng/ml vs. 1.86 ±0.13 ng/ml, respectively. There was no significant correlation between serum visfatin levels and any anthropometric or any metabolic parameters in patients with metabolic syndrome or the control group. Conclusions: The results of this study showed that serum visfatin level was decreased in patients with MetS, indicating that Visfatin cannot be considered as a new proinflammatory adipocytokine for the metabolic syndrome.

Keywords: Visfatin, Metabolic syndrome, Adipokine
Full-Text [PDF 284 kb]   (3233 Downloads)    
Type of Study: Original |
Received: 2009/08/18 | Published: 2010/03/15
Add your comments about this article
Your username or Email:


XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Foroughi M, Hosseinzadeh M, Zahediasl S, Hoseinpanah F, Momenan A, Eshraghiyan M et al . Serum Visfatin Concentration in Patients with Metabolic Syndrome. Iranian Journal of Endocrinology and Metabolism 2010; 11 (2) :151-157
URL: http://ijem.sbmu.ac.ir/article-1-759-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 11, Issue 2 (3-2010) Back to browse issues page
مجله ی غدد درون‌ریز و متابولیسم ایران، دو ماهنامه  پژوهشی مرکز تحقیقات غدد درون‌ریز و متابولیسم، Iranian Journal of Endocrinology and Metabolism
Persian site map - English site map - Created in 0.05 seconds with 37 queries by YEKTAWEB 4624